Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs. In the present study, we analyzed the value of 18F-FDG PET-CT in assessing the malignant potential of gGISTs before treatment. Methods: Patients who were diagnosed with gGIST by pathology and underwent 18F-FDG PET/CT at the same time were collected. The clinicopathological features of 26 patients with gGISTs were retrospectively analyzed at last. The gGIST risk classification was graded according to the US National Institutes of Health (NIH) GIST risk classification criteria [2008]. Lesions were classified as malignant group (moderate- or high-risk category) and benign group (low- or very low-risk category) according to pathology. The relationship between the maximal standard uptake value (SUVmax) and GIST risk category, tumor diameter, Ki-67 index, and mitotic count was analyzed. The cut-off level of SUVmax for the diagnosis of malignant gGIST with the highest sensitivity was calculated based on the receiver-operating characteristic (ROC) curve. Results: The SUVmax, tumor diameter, Ki-67 index, and mitotic count of the 26 gGIST patients were 5.90±4.49, 7.40±4.92 cm, 7.62%±11.76%, (5.96±3.19)/50 high-power field (HPF), respectively. SUVmax was significantly correlated with GIST risk category, Ki-67 index, and mitotic count (r=0.855, 0.860, and 0.690, all P<0.01) but not with tumor diameter (r=0.383, P=0.054). The SUVmax of gGIST was 7.00±4.57 in the malignant group (moderate or high NIH risk category in 20 patients), which was significantly different from that (2.25±0.77) in the benign group (low or extremely low NIH risk category in 6 patients) (t=4.566, P<0.01). ROC curve analysis showed that a SUVmax cut-off of 2.60 was most sensitive for predicting malignant gGIST. When the area under the curve was 0.967, the sensitivity was 100% and the specificity was 83.3%. Conclusions: SUVmax may be used as a complementary indicator for predicting the malignant potential of gGISTs before treatment. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs. In the present study, we analyzed the value of 18F-FDG PET-CT in assessing the malignant potential of gGISTs before treatment. Methods: Patients who were diagnosed with gGIST by pathology and underwent 18F-FDG PET/CT at the same time were collected. The clinicopathological features of 26 patients with gGISTs were retrospectively analyzed at last. The gGIST risk classification was graded according to the US National Institutes of Health (NIH) GIST risk classification criteria [2008]. Lesions were classified as malignant group (moderate- or high-risk category) and benign group (low- or very low-risk category) according to pathology. The relationship between the maximal standard uptake value (SUVmax) and GIST risk category, tumor diameter, Ki-67 index, and mitotic count was analyzed. The cut-off level of SUVmax for the diagnosis of malignant gGIST with the highest sensitivity was calculated based on the receiver-operating characteristic (ROC) curve. Results: The SUVmax, tumor diameter, Ki-67 index, and mitotic count of the 26 gGIST patients were 5.90±4.49, 7.40±4.92 cm, 7.62%±11.76%, (5.96±3.19)/50 high-power field (HPF), respectively. SUVmax was significantly correlated with GIST risk category, Ki-67 index, and mitotic count (r=0.855, 0.860, and 0.690, all P<0.01) but not with tumor diameter (r=0.383, P=0.054). The SUVmax of gGIST was 7.00±4.57 in the malignant group (moderate or high NIH risk category in 20 patients), which was significantly different from that (2.25±0.77) in the benign group (low or extremely low NIH risk category in 6 patients) (t=4.566, P<0.01). ROC curve analysis showed that a SUVmax cut-off of 2.60 was most sensitive for predicting malignant gGIST. When the area under the curve was 0.967, the sensitivity was 100% and the specificity was 83.3%. Conclusions: SUVmax may be used as a complementary indicator for predicting the malignant potential of gGISTs before treatment. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
18F-fluorodeoxyglucose (18F-FDG); Gastric gastrointestinal stromal tumors (gGISTs); maximum standardized uptake value (SUVmax); positron emission tomography (PET); risk classification
Authors: Margaret von Mehren; John M Kane; Marilyn M Bui; Edwin Choy; Mary Connelly; Sarah Dry; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; Jade Homsi; Vicki Keedy; Ciara M Kelly; Edward Kim; David Liebner; Martin McCarter; Sean V McGarry; Christian Meyer; Alberto S Pappo; Amanda M Parkes; I Benjamin Paz; Ivy A Petersen; Matthew Poppe; Richard F Riedel; Brian Rubin; Scott Schuetze; Jacob Shabason; Jason K Sicklick; Matthew B Spraker; Melissa Zimel; Mary Anne Bergman; Giby V George Journal: J Natl Compr Canc Netw Date: 2020-12-02 Impact factor: 11.908
Authors: Seong Ji Choi; Kwan Hong Lee; Chan Kyoo Yoo; Jai Hoon Yoon; Ki Seok Jang; Youn Jeong Kim; Hang Lak Lee Journal: J Clin Med Date: 2021-02-10 Impact factor: 4.241